血脂领域的新进展

耿慧; 刘梅林

doi:10.13201/j.issn.1001-1439.2014.02.003

血脂领域的新进展

耿慧,
刘梅林^,

- 北京大学第一医院老年内科(北京, 100034)
基金项目:
国家科技支撑计划项目 No:2012BAI37B05)

详细信息

通讯作者: 刘梅林,E-mail:meilinliu@yahoo.com

中图分类号: R589.2

收稿日期: 2013-04-07

修回日期: 2013-08-29

Update on the management of dyslipidemia

GENG Hui,
LIU Meilin^,

- Department of Geriatrics, First Hospital, Peking University, Beijing, 100034, China

More Information

Corresponding author: LIU Meilin, E-mail: meilinliu@yahoo.com

Received Date: 07 April 2013

Revised Date: 29 August 2013

摘要

摘要: 血脂异常是心脑血管疾病重要的危险因素。近年来, 血脂领域相关研究促进了心血管病防治理念的更新。新的研究表明, PCSK9单克隆抗体未来有可能成为血脂, 尤其是家族性高胆固醇血症治疗的新突破;烟酸类药物联合他汀类药物缺乏更多心血管保护作用;他汀类药物的安全性以及在特殊人群中的应用引起更多关注。本文对血脂领域的国际大规模临床试验结果及相关进展进行回顾。
- 调脂治疗 /
- PCSK9 /
- 烟酸 /
- 他汀 /
- 安全性 /
- 临床试验
Abstract: Dyslipidemia is an important risk factor for cardiovascular and cerebrovascular disease.New researches on management of dyslipidemia promote updates in prevention and treatment of cardiovascular disease.Recent studies show that pharmacologic inhibition of PCSK9might be a promising therapeutic area in lowering LDL cholesterol levels, especially in patients with familial hypercholesterolemia.Extended-release niacin with laropiprant offered no benefits beyond statin therapy alone in reducing the risk of major vascular events.Safety and application in specific population of statin therapy have been addressed to more attention.This review focus on recent clinical trials and management of dyslipidemia.
- dyslipidemia /
- PCSK9 /
- niacin /
- statins /
- safety /
- clinical trials

HTML全文

参考文献(31)

[1]	STEIN E A, MELLIS S, YANCOPOULOS G S, et al.Effect of a monoclonal antibody to PCSK9on LDL cholesterol[J].N Engl J Med, 2012, 366:1108-1118.
[2]	STEIN E A, GIPE D, BERGERON J, et al.Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy:aphase 2randomised controlled trial[J].Lancet, 2012, 380:29-36.
[3]	KOREN M J, SCOTT R, KIM J B, et al.Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9as monotherapy in patients with hypercholesterolaemia (MENDEL):a randomised, double-blind, placebo-controlled, phase 2study[J].Lancet, 2012, 380:1995-2006.
[4]	SULLIVAN D, OLSSON A G, SCOTT R, et al.Effect of a monoclonal antibody to PCSK9on low-density lipoprotein cholesterol levels in Statin-Intolerant Patients-The GAUSS Randomized Trial[J].JAMA, 2012, 308:E1-E10.
[5]	GIUGLIANO R P, DESAI N R, KOHLI P, et al.Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57):A randomised, placebo-controlled, dose-ranging, phase 2study[J].Lancet, 2012, 380:2007-2017.
[6]	RAAL F, SCOTT R, SOMARATNE R, et al.Lowdensity lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9serine protease in patients with heterozygous familial hypercholesterolemia:the Reduction of LDL-C with PCSK9Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial[J].Circulation, 2012, 126:2408-2417.
[7]	The AIM-HIGH Investigators.Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy[J].N Engl J Med, 2011, 365:2255-2267.
[8]	HPS2-THRIVE Collaborative Group.HPS2-THRIVE ran-domized placebo-controlled trial in 25 673high-risk patients of ER niacin/laropiprant:trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment[J].Eur Heart J, 2013, doi:10.1093/eurheartj/eht055.
[9]	LANDMESSER U.The difficult search for a 'partner' of statins in lipid-targeted prevention of vascular events:the re-emergence and fall of niacin[J].Eur Heart J, 2013, doi:10.1093/eurheartj/eht064.
[10]	COHEN J D, BRINTON E A, ITO M K, et al.Understanding Statin Use in America and Gaps in Patient Education (USAGE):An internet-based survey of10, 138current and former statin users[J].J Clin Lipidol, 2012, 6:208-215.
[11]	COLLINS G S, ALTMAN D G.Predicting the adverse risk of Statin treatment:an independent and external validation of Qstatin risk scores in the UK[J].Heart, 2012, 98:1091-1097.
[12]	ATHYROS V G, TZIOMALOS K, GOSSIOS T D, et al.Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study:apost-hoc analysis[J].Lancet, 2010, 376:1916-1922.
[13]	RIDKER P M, PRADHAN A, MACFADYEN J G, et al.Cardiovascular benefits and diabetes risks of statin therapy in primary prevention:an analysis from the JUPITER trial[J].Lancet, 2012, 380:565-571.
[14]	BERNICK C, KATZ R, SMITH N L, et al.Statins and cognitive function in the elderly:the Cardiovascular Health Study[J].Neurology, 2005, 65:1388-1394.
[15]	OTT B, Daiello L, Springate B, et al.Do statin drugs impair cognition?A systematic review and meta-analysis[J].AAIC, 2013, 9 (Suppl):P666-666.
[16]	DI SCIASCIO G, PATTI G, PASCERI V, et al.Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention:title and subtitle break.results of the ARMYDA-RECAPTURE (atorvastatin for reduction of myocardial damage during angioplasty) randomized trial[J].J Am Coll Cardiol, 2009, 54:558-565.
[17]	BRIGUORI C, VISCONTI G, FOCACCIO A, et al.Novel approaches for preventing or limiting events (Naples) Ⅱtrial:title and subtitle break.impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction[J].J Am Coll Cardiol, 2009, 54:2157-2163.
[18]	Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC).ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation[J].Eur Heart J, 2012, 33:2569-2619.
[19]	BLAHA M J, NASIR K, BLUMENTHAL R S.Statin therapy for healthy men identified as "increased risk"[J].JAMA, 2012, 307:1489-1490.
[20]	REDBERG R F, KATZ M H.Healthy men should not take statins[J].JAMA, 2012, 307:1491-1492.
[21]	BECKMAN J A.Use of statins in healthy men[J].JAMA, 2012, 308:666-667.
[22]	Cholesterol Treatment Trialists' (CTT) CollaborATORS, MIHAYLOVA B, EMBERSON J, et al.The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease:meta-analysis of individual data from 27randomised trials[J].Lancet, 2012, 380:581-590.
[23]	NIELSEN S F, NORDESTGAARD B G, and BOJESEN S E.Statin use and reduced cancer-related mortality[J].N Engl J Med, 2012, 367:1792-802.
[24]	LENIHAN D J.Statins in preparation for chemotherapy:"do these medications help your fitness for battle?"[J].J Am Coll Cardiol, 2012, 60:2391-2392.
[25]	FROHLICH G M, RUFIBACH K, ENSELEIT F, et al.Statins and the risk of cancer after heart transplantation[J].Circulation, 2012, 126:440-447.
[26]	MARCELLA S W, DAVID A, OHMAN-STRICKLAND P A, et al.Statin use and fatal prostate cancer:A matched case-control study[J].Cancer, 2012, 118:4046-4052.
[27]	CULVER A L, OCKENE I S, BALASUBRAMANIAN R, et al.Statin use and risk of diabetes mellitus in postmenopausal women in the women's health initiative[J].Arch Intern Med, 2012, 172:144-152.
[28]	GUTIERREZ J, RAMIREZ G, RUNDEK T, et al.Statin therapy in the prevention of recurrent cardiovascular events:A Sex-Based Meta-analysis[J].Arch Intern Med, 2012, 172:909-919.
[29]	QUINTAVALLE C, FIORE D, DE MICCO F, et al.Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury[J].Circulation, 2012, 126:3008-3016.
[30]	LEONCINI M, TOSO A, MAIOLI M, et al.Early high-dose rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome:The PRATO-ACS (protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome) study[C].J Am Coll Cardiol, 2013, doi:10.1016/j.jacc.2013.04.105.
[31]	BOEKHOLDT S M, ARSENAULT B J, MORA S.Association of LDL cholesterol, non-HDL Cholesterol, and apolipoprotein B Levels with risk of cardiovascular events among patients treated with statins[J].JAMA, 2012, 307:1302-1309.